Programmed death ligand-1/programmed death-1 inhibition therapy and programmed death ligand-1 expression in urothelial bladder carcinoma

After two decades of unchanged paradigms, the treatment strategies for advanced urothelial bladder cancer have been revolutionized by emerging programmed death ligand-1 (PD-L1)/programmed death-1 (PD1) inhibition therapy. Increased evidence is demonstrating the efficacy of PD-L1/PD1 inhibition thera...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Wei-Bo Yu, Jian-Yu Rao
Formato:	article
Lenguaje:	EN
Publicado:	KeAi Communications Co., Ltd. 2019
Materias:	Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/d9de201c2d614d868469c89bd5ca9cae
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:d9de201c2d614d868469c89bd5ca9cae
record_format	dspace
spelling	oai:doaj.org-article:d9de201c2d614d868469c89bd5ca9cae2021-12-02T16:02:25ZProgrammed death ligand-1/programmed death-1 inhibition therapy and programmed death ligand-1 expression in urothelial bladder carcinoma2095-882X10.1016/j.cdtm.2019.08.003https://doaj.org/article/d9de201c2d614d868469c89bd5ca9cae2019-09-01T00:00:00Zhttp://www.sciencedirect.com/science/article/pii/S2095882X19300684https://doaj.org/toc/2095-882XAfter two decades of unchanged paradigms, the treatment strategies for advanced urothelial bladder cancer have been revolutionized by emerging programmed death ligand-1 (PD-L1)/programmed death-1 (PD1) inhibition therapy. Increased evidence is demonstrating the efficacy of PD-L1/PD1 inhibition therapy in both second-line and first-line settings. However, the percentage of patients who benefit from anti-PD-L1/anti-PD1 therapy is still low. Many questions have been raised in the development of biomarker-driven approaches for disease classification and patient selection. In this perspective, we discuss PD-L1/PD1 expression in urothelial bladder carcinoma, review approved anti-PD-L1/anti-PD1 agents for bladder cancer treatment and current ongoing studies investigating combination treatment strategies, and explore PD-L1 expression status for the evaluation of bladder cancer immunotherapy. Keywords: Immune checkpoint therapy, Urothelial carcinoma, Bladder cancer, Programmed death-ligand 1, Programmed death-1Wei-Bo YuJian-Yu RaoKeAi Communications Co., Ltd.articleMedicine (General)R5-920ENChronic Diseases and Translational Medicine, Vol 5, Iss 3, Pp 170-177 (2019)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine (General) R5-920
spellingShingle	Medicine (General) R5-920 Wei-Bo Yu Jian-Yu Rao Programmed death ligand-1/programmed death-1 inhibition therapy and programmed death ligand-1 expression in urothelial bladder carcinoma
description	After two decades of unchanged paradigms, the treatment strategies for advanced urothelial bladder cancer have been revolutionized by emerging programmed death ligand-1 (PD-L1)/programmed death-1 (PD1) inhibition therapy. Increased evidence is demonstrating the efficacy of PD-L1/PD1 inhibition therapy in both second-line and first-line settings. However, the percentage of patients who benefit from anti-PD-L1/anti-PD1 therapy is still low. Many questions have been raised in the development of biomarker-driven approaches for disease classification and patient selection. In this perspective, we discuss PD-L1/PD1 expression in urothelial bladder carcinoma, review approved anti-PD-L1/anti-PD1 agents for bladder cancer treatment and current ongoing studies investigating combination treatment strategies, and explore PD-L1 expression status for the evaluation of bladder cancer immunotherapy. Keywords: Immune checkpoint therapy, Urothelial carcinoma, Bladder cancer, Programmed death-ligand 1, Programmed death-1
format	article
author	Wei-Bo Yu Jian-Yu Rao
author_facet	Wei-Bo Yu Jian-Yu Rao
author_sort	Wei-Bo Yu
title	Programmed death ligand-1/programmed death-1 inhibition therapy and programmed death ligand-1 expression in urothelial bladder carcinoma
title_short	Programmed death ligand-1/programmed death-1 inhibition therapy and programmed death ligand-1 expression in urothelial bladder carcinoma
title_full	Programmed death ligand-1/programmed death-1 inhibition therapy and programmed death ligand-1 expression in urothelial bladder carcinoma
title_fullStr	Programmed death ligand-1/programmed death-1 inhibition therapy and programmed death ligand-1 expression in urothelial bladder carcinoma
title_full_unstemmed	Programmed death ligand-1/programmed death-1 inhibition therapy and programmed death ligand-1 expression in urothelial bladder carcinoma
title_sort	programmed death ligand-1/programmed death-1 inhibition therapy and programmed death ligand-1 expression in urothelial bladder carcinoma
publisher	KeAi Communications Co., Ltd.
publishDate	2019
url	https://doaj.org/article/d9de201c2d614d868469c89bd5ca9cae
work_keys_str_mv	AT weiboyu programmeddeathligand1programmeddeath1inhibitiontherapyandprogrammeddeathligand1expressioninurothelialbladdercarcinoma AT jianyurao programmeddeathligand1programmeddeath1inhibitiontherapyandprogrammeddeathligand1expressioninurothelialbladdercarcinoma
_version_	1718385301624193024

Programmed death ligand-1/programmed death-1 inhibition therapy and programmed death ligand-1 expression in urothelial bladder carcinoma

Ejemplares similares